Novel nanotherapeutics for combatting pneumonic plague
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- HT942523D0011
- Awardee
-
Eitr Biologics, Inc. UEI HX49LZLY32G5
- Awarding agency
-
Defense Health Agency
Department of Defense
- Task orders
- 7 $4,711,051 obligated
Award facts
- Opportunity
-
- HT942523R0061 Solicitation number
- Combined order value
-
- $4,711,051 Current, with exercised options
- $4,711,651 Potential, with all options
- Last date to order 64% complete
- IDV ceiling 41% used
- $11,545,410.63
- Maximum order
- $4,390,205.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- PSC
- AJ11 General Science And Technology R&D Services; General Science And Technology; Basic Research
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
The Defense Health Agency awarded a single-award indefinite-delivery contract to Eitr Biologics, Inc. on August 15, 2023, with a ceiling of $11,545,410.63 and completion date of August 14, 2028, for development of novel nanotherapeutics targeting pneumonic plague caused by Yersinia pestis.
No set-aside was used. Place of performance is San Diego, California.
The IDIQ funds development of nanotherapeutic and antibody-based medical countermeasures against biological threats, with particular emphasis on plague and broad-spectrum viral pathogens. Work includes assessment of nanotherapeutic approaches through in vitro and in vivo assays, antibody discovery platforms, and engineering of novel therapeutics targeting Yersinia pestis outer membrane proteins.
Recent delivery orders issued under this IDIQ include a $1,864,756.31 award (September 20, 2024, through December 31, 2025) for novel nanotherapeutics development; a $926,999.13 order (February 1, 2026, through December 31, 2027) for bispecific broad-spectrum nanobody development; a $269,999.45 order (April 1, 2026, through March 31, 2027) for novel bispecific broad-spectrum nanobody therapeutics; a $499,896.06 award (July 1, 2024, through June 30, 2025) for development of a novel ODIN therapeutic medical countermeasure against pneumonic unencapsulated Yersinia pestis; a $299,999.66 order (July 1, 2025, through June 30, 2026) for novel nanotherapeutics development; and a $100,000 order (July 1, 2026, through June 30, 2027) for novel bispecific broad-spectrum nanobody development. All orders are firm fixed-price and performed in San Diego, California.
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract HT942523D0011?
HT942523D0011 was awarded to Eitr Biologics, Inc. by Defense Health Agency (Department of Defense) on August 15, 2023.
How much is contract HT942523D0011 worth?
Orders under HT942523D0011 have obligated $4,711,051. Their combined potential value, with all options, is $4,711,651. HT942523D0011's own ceiling is $11,545,411. A single order can be worth up to $4,390,205.
How many orders have been placed under contract HT942523D0011?
7 orders have been placed under HT942523D0011, the latest on July 1, 2026.
Who can order from contract HT942523D0011?
HT942523D0011 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract HT942523D0011 competed?
The extent of competition for HT942523D0011 was not competed. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV